Compare Atlassian Corporation PLC (TEAM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs Vertex Pharmaceuticals Incorporated — how do they compare? Atlassian Corporation PLC trades at $178.15 (market cap $44.66B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3× Atlassian Corporation PLC's market cap. Which is the better fit depends on your goals.
| TEAM | VRTX | |
|---|---|---|
Market Cap | $44.66B | $134.06B |
Sector | Technology | Health |
52-Week High | $194.68 | $557.96 |
52-Week Low | $57.15 | $376.62 |
Enterprise Value | $44.65B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $176.42, down 6.94% on the day, despite strong recent performance with three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with support at $173 and resistance at $182. Revenue growth continues at $5.22B (2025) with improving margins, though the company remains unprofitable with a -0.82% net income margin. Analyst consensus is strongly bullish with 30 buy ratings and a $179.81 price target, while recent news highlights AI integration driving cloud growth.
TEAM presents a growth-oriented investment with significant upside potential from AI adoption and market expansion, but carries risks from persistent losses, premium valuation (P/S 6.98), and insider selling. The path to profitability remains key, with projected net losses narrowing to -$54M in 2026. Investors should weigh strong analyst support against high execution demands in a competitive SaaS landscape.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
